Table 4 Patient characteristics of the ICB cohort
From: Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
Characteristics | Number N | (%) |
|---|---|---|
All patients | 129 | 100 |
Age in years, (range) | 67.11, (28−92) | |
Gender | ||
Female | 50 | 38.8 |
Male | 79 | 61.2 |
Site of melanoma metastases | ||
Cutaneous metastases | 62 | 48.1 |
Lymph node metastases | 37 | 28.7 |
Lung metastases | 13 | 10.1 |
Brain metastases | 11 | 8.5 |
Abdominal metastases | 6 | 4.7 |
BRAF mutation status | ||
BRAF wild type | 84 | 65.1 |
BRAF mutated | 42 | 32.6 |
Unknown | 3 | 2.3 |
Response to anti-PD-1 blockade | ||
Progressive disease (PD) | 58 | 45.0 |
Partial response (PR) | 39 | 30.2 |
Stable disease (SD) | 8 | 6.2 |
Complete response (CR) | 22 | 17.0 |
Unknown | 2 | 1.6 |
Therapeutic regimen | ||
Anti-PD-1 monotherapy | 68 | 52.7 |
Ipilimumab, anti-PD-1 monotherapy | 12 | 9.3 |
Ipilimumab + nivolumab | 17 | 13.2 |
Ipilimumab, ipilimumab + nivolumab | 2 | 1.5 |
Anti-PD-1 monotherapy, ipilimumab + nivolumab | 30 | 23.3 |
Medical center | ||
University Hospital Bonn—dermatology | 104 | 80.6 |
University Hospital Bonn—oncology | 5 | 3.9 |
University Hospital Bonn—neurosurgery/-oncology | 4 | 3.1 |
Kantonsspital St. Gallen, Spital Grabs, Spital Wil, Spital Flawil | 16 | 12.4 |